In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Genocea secures up to $27mm in debt financing from Hercules, plus $2mm in equity financing

Executive Summary

Nine months after going public, Genocea Biosciences Inc. (T-cell vaccines for infectious diseases) secured up to $27mm in debt financing from Hercules Technology Growth Capital, which provided $12mm up front. At its option, Genocea can draw down another $5mm no later than June 30, 2015, and two additional tranches of $5mm on or before December 15, 2015. The tranches are subject to Phase II clinical milestones for its GEN003 and GEN004, and the close of future equity financing. Hercules also purchased $2mm in Genocea equity--223k common shares at $8.95 each (a slight premium).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Financing
    • Nonconvertible Debt
    • Private Investment in Public Equity
    • Private Placement

Related Companies